September 25, 2020 DevilFoehn

Tenant Spotlight: Ocugen, Inc.


Company Size: 12

What’s your mission?
Our mission is to develop gene therapies to cure blindness diseases.

What products or services do you sell / provide?
Our modifier gene therapy program is in development to treat Retinitis Pigmentosa and dry age-related macular degeneration. We are also developing on a novel biologic to treat major retinal diseases.

What is the story behind your company and what are you known for?
Modifier gene therapy program has potential for one product to treat many diseases representing a unique approach in ophthalmology. Technology was licensed from Harvard Medical School.

Accolades to note:
Four FDA orphan drug designations for OCU400 gene therapy. Initiation of four Phase 1/2 trials within 1-2 years, with data readouts beginning in 2022. Strategic partnership with CanSinoBio sets a clear path for critical gene therapy manufacturing.

Stay Connected With Ocugen, Inc.